Results 111 to 120 of about 36,830 (259)

JAK Inhibitors in Psoriatic–Atopic Dermatitis Overlap: A Four‑Case Series

JEADV Clinical Practice, EarlyView.
ABSTRACT Overlap between psoriasis and atopic dermatitis (AD) poses diagnostic and therapeutic challenges; monoclonal antibodies targeting a single axis may improve one component while worsening the other [1]. Janus kinase (JAK) inhibitors act pleiotropically and may provide simultaneous control of psoriatic and eczematous inflammation [2].
Eleonora Bongiovanni, Francois Rosset, Isotta Giunipero di Corteranzo, Lorenzo Bellando, Rebecca Senetta, Simone Ribero, Pietro Quaglino   +6 more
wiley   +1 more source

Metabolic Profiling in Rheumatoid Arthritis, Psoriatic Arthritis, and Psoriasis: Elucidating Pathogenesis, Improving Diagnosis, and Monitoring Disease Activity. [PDF]

J Pers Med, 2022
Dorochow E, Köhm M, Hahnefeld L, Gurke R.   +3 more
europepmc   +1 more source

Correspondence on 'Role of joint damage, malalignment and inflammation in articular tenderness in rheumatoid arthritis, psoriatic arthritis and osteoarthritis'. [PDF]

Ann Rheum Dis, 2023
Dumoulin QA, Matthijssen XME, Wouters F, Krijbolder DI, Niemantsverdriet E, van der Helm-van Mil AHM.   +5 more
europepmc   +1 more source

A Cross‐Sectional Survey Study Assessing the Quality of Life and Sleep in Spanish Psoriasis Patients

JEADV Clinical Practice, EarlyView.
Psoriasis impacts quality of life (QOL) and sleep (QOS), yet dermatology assessments often do not evaluate sleep. The Short‐form health survey (SF‐36) and Pittsburg sleep quality index (PSQI) further investigated patients’ QOL and QOS. Particularly women, unemployed patients, and those that use sleep medications had worse QOS and QOL.
Gabriela Piñero‐Crespo, María Isabel del Pino Rincón, Lilia Correa‐Selm, Raquel Hernández Sánchez, Amalia Pérez‐Gil   +4 more
wiley   +1 more source

Epidemiology, genetics and management of psoriatic arthritis 2013: focus on developments of who develops the disease, its clinical features, and emerging treatment options

Psoriasis: Targets and Therapy, 2013
Muhammad Haroon,1 Oliver FitzGerald,1 Robert Winchester2 1Department of Rheumatology, St Vincent's University Hospital, Dublin, Ireland; 2Division of Rheumatology, Columbia University College of Physicians and Surgeons, New York, NY, USA Abstract ...
Haroon M, FitzGerald O, Winchester R
doaj  

Rheumatoid arthritis, psoriatic arthritis, and axial spondyloarthritis epidemiology in England from 2004 to 2020: An observational study using primary care electronic health record data. [PDF]

Lancet Reg Health Eur, 2022
Scott IC, Whittle R, Bailey J, Twohig H, Hider SL, Mallen CD, Muller S, Jordan KP.   +7 more
europepmc   +1 more source

DERMACLEAR: AI‐Powered Insights Into Four Chronic Inflammatory Skin Diseases in Spain

JEADV Clinical Practice, EarlyView.
Using an AI‐enhanced analysis of electronic health records from nearly 50,000 patients, the DERMACLEAR study provides real‐world insights into the prevalence, clinical complexity, comorbidities and treatment patterns of HS, CU, PsO and AD in Spain.
Ana Giménez‐Arnau, Javier Ortiz de Frutos, Raquel Rivera‐Díaz, Lluís Puig, Jaume Notario Rosa, José Luis López‐Estebaranz, Vicente García‐Patos Briones, Ana Martín‐Santiago, José Ignacio Rojo‐Laguna, Elisabet Fernández‐Martínez, Lara Gómez‐Labrador, Esteban Daudén   +11 more
wiley   +1 more source

Pooled safety results across phase 3 randomized trials of intravenous golimumab in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis. [PDF]

Arthritis Res Ther, 2022
Husni ME, Deodhar A, Schwartzman S, Chakravarty SD, Hsia EC, Leu JH, Zhou Y, Lo KH, Kavanaugh A.   +8 more
europepmc   +1 more source

Paradoxical Alopecia Areata Induced by IL‐17 and IL‐23 Inhibitors: A Systematic Review

JEADV Clinical Practice, EarlyView.
This systematic review identifies consistent clinical patterns of alopecia areata associated with IL‐17 and IL‐23 inhibitors, most frequently involving secukinumab and ustekinumab. Disease severity varied widely, and management often required biologic discontinuation or therapeutic switching.
Isabella Kamholtz, Simonetta I. Gaumond, Joaquin J. Jimenez   +2 more
wiley   +1 more source

Real-Life Retention Rates and Reasons for Switching of Biological DMARDs in Rheumatoid Arthritis, Psoriatic Arthritis, and Ankylosing Spondylitis. [PDF]

Front Med (Lausanne), 2021
Bhushan V, Lester S, Briggs L, Hijjawi R, Shanahan EM, Pontifex E, Ninan J, Hill C, Cai F, Walker J, Goldblatt F, Wechalekar MD.   +11 more
europepmc   +1 more source